LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Quidel Corp

Uždarymo kaina

28.55 -3.15

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.35

Max

30.18

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

6,600

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+40.54% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

254M

1.7B

Ankstesnė atidarymo kaina

31.7

Ankstesnė uždarymo kaina

28.55

Quidel Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-17 23:01; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025-09-17 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025-09-17 21:59; UTC

Uždarbis

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025-09-17 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-09-17 23:39; UTC

Rinkos pokalbiai

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025-09-17 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025-09-17 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025-09-17 21:00; UTC

Uždarbis

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025-09-17 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025-09-17 19:07; UTC

Rinkos pokalbiai

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025-09-17 18:43; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025-09-17 18:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025-09-17 18:20; UTC

Rinkos pokalbiai

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025-09-17 18:14; UTC

Rinkos pokalbiai

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025-09-17 17:59; UTC

Rinkos pokalbiai

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025-09-17 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025-09-17 17:06; UTC

Įsigijimai, susijungimai, perėmimai

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025-09-17 16:51; UTC

Uždarbis

Correct: Exor 1H Net Loss -EUR624M

2025-09-17 16:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 16:34; UTC

Rinkos pokalbiai

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025-09-17 16:25; UTC

Uždarbis

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025-09-17 16:23; UTC

Uždarbis

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Akcijų palyginimas

Kainos pokytis

Quidel Corp Prognozė

Kainos tikslas

By TipRanks

40.54% į viršų

12 mėnesių prognozė

Vidutinis 41.5 USD  40.54%

Aukščiausias 62 USD

Žemiausias 26 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quidel Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

4

Pirkti

3

Laikyti

1

Parduoti

Finansinės naujienos

$

Apie bendrovę Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat